KennethMAlgazyMDPhD

PubMed

• 1 citations
  A Single-institution Comparison of Cetuximab, Carboplatin, and Paclitaxel Induction Chemotherapy Followed by Chemoradiation (CRT) Versus CRT for Locally Advanced Squam...
  Surbhi Grover, Nandita Mitra, Fei Wan, John N. Lukens, Sonam Sharma, Jessica Bauman, Farzad Masroor, Roger B. Cohen, Arati Desai, Kenneth M. Algazy, Michelle Alonso-Ba...> ;American Journal of Clinical Oncology. 2016 Oct 1
• 315 citations
  Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma
  Reshma Rangwala, Yunyoung C. Chang, Janice Hu, Kenneth M. Algazy, Tracey L. Evans, Leslie A. Fecher, Lynn M. Schuchter, Drew A. Torigian, Jeffrey T. Panosian, Andrea B...> ;Autophagy. 2014 May 20
• 21 citations
  Induction chemotherapy with cetuximab, carboplatin and paclitaxel for the treatment of locally advanced squamous cell carcinoma of the head and neck
  Jessica Bauman, Corey J. Langer, Harry Quon, Kenneth M. Algazy, Alexander Lin, Arati Desai, Faith Mutale, Jared Weiss> ;Experimental and Therapeutic Medicine. 2013 Apr 1
• 28 citations
  A Randomized Phase II Study of Cetuximab Every 2 Weeks at Either 500 or 750 mg/m2 for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Cancer
  Matthew G. Fury, Eric J. Sherman, Donna Lisa, Neeraj Agarwal, Kenneth M. Algazy, Bruce Brockstein, Corey J. Langer, Dean Lim, Ranee Mehra, Sandeep K. Rajan, Susan H. K...> ;Journal of the National Comprehensive Cancer Network. 2012 Nov 1
• A randomized phase II study of cetuximab (C) every 2 weeks at either 500 or 750 mg/m2 for patients (Pts) with recurrent or metastatic (R/M) head and neck squamous cell...
  Fury MG, Sherman EJ, Lisa DM, Agarwal N, Algazy KM, Brockstein B, Langer CJ, Lim D, Mehra R, Rajan SK, Jafri N, Korte S, Lipson B, Yunus F, Tanvetyanon T, Smith-Marron...> ;J. Clin. Oncol.. 2011-05-20
• 8 citations
  Spontaneous smoking cessation before lung cancer diagnosis.
  Barbara G. Campling, Bradley N. Collins, Kenneth M. Algazy, Robert A. Schnoll, Miu Lam> ;Journal of Thoracic Oncology. 2011 Mar 1
• 3 citations
  Phase I study of Paclitaxel given by seven-week continuous infusion concurrent with radiation therapy for locally advanced non-small cell lung cancer.
  David I. Rosenthal, Clifton D. Fuller, Mitchell Machtay, Kenneth M. Algazy, Dan M. Meyer, Larry R. Kaiser, Denise A. Yardley, Megan E. Loiacano, David P. Carbone> ;Journal of Thoracic Oncology. 2006 Jan 1
• 14 citations
  Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania.
  M. L. Veronese, Kenneth M. Algazy, Lisa Bearn, Beth Eaby, Jane B. Alavi, Tracey L. Evans, James P. Stevenson, Justine Shults> ;Cancer Investigation. 2005 Jan 1
• 27 citations
  A population-based study of lung carcinoma in Pennsylvania: comparison of Veterans Administration and civilian populations.
  Barbara G. Campling, Wei-Ting Hwang, Jiameng Zhang M.D., Stephanie Thompson, Leslie A. Litzky, Anil Vachani, Ilene M. Rosen, Kenneth M. Algazy> ;Cancer. 2005 Aug 15
• Mortality from prostate cancer (PC) in Pennsylvania(PA) in civilian versus Veterans Administration (VA) populations.
  Lubiniecki GM, Chen Z, Thompson S, Algazy KM> ;J. Clin. Oncol.. 2004-07-15
• 14 citations
  Phase I trial of UFT/leucovorin and irinotecan in patients with advanced cancer.
  M. L. Veronese, James P. Stevenson, Weijing Sun, Maryann Redlinger, Kenneth M. Algazy, Bruce J. Giantonio, Stephen M. Hahn, David J. Vaughn, Caroline F. Thorn, Alexand...> ;European Journal of Cancer. 2004 Mar 1
• 42 citations
  Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non–small cell lung carcinoma: long-term results and associations with patholog...
  Mitchell Machtay, Jason H. Lee, James P. Stevenson, Joseph B. Shrager, Kenneth M. Algazy, Joseph Treat, Larry R. Kaiser> ;The Journal of Thoracic and Cardiovascular Surgery. 2004 Jan 1
• 9 citations
  A phase I, dose escalation trial of ZD0473, a novel platinum analogue, in combination with gemcitabine.
  Keith T. Flaherty, James P. Stevenson, Maryann Redlinger, Kenneth M. Algazy, Bruce J. Giantonio, Peter J. O'Dwyer> ;Cancer Chemotherapy and Pharmacology. 2004 Jan 29
• 1 citations
  Phase I trial of the antifolate ZD9331 in combination with cisplatin in patients with refractory solid malignancies.
  Joshua H. Bilenker, James P. Stevenson, Keith T. Flaherty, Kenneth M. Algazy, Kathy McLaughlin, Daniel G. Haller, Bruce J. Giantonio, M. Koehler, J. E. Garcia-Vargas, ...> ;Cancer Chemotherapy and Pharmacology. 2004 Jan 13
• 5 citations
  Dose escalation study of tezacitabine in combination with cisplatin in patients with advanced cancer
  Keith T. Flaherty, James P. Stevenson, Maryann Gallagher, Bruce J. Giantonio, Kenneth M. Algazy, Weijing Sun, Daniel G. Haller, Peter J. O'Dwyer> ;Cancer. 2003 Apr 15
• 14 citations
  Phase I and pharmacokinetic trial of the proapoptotic sulindac analog CP-461 in patients with advanced cancer.
  Weijing Sun, James P. Stevenson, James M. Gallo, Maryann Redlinger, Daniel G. Haller, Kenneth M. Algazy, Bruce J. Giantonio, Hector Alila, Peter J. O'Dwyer> ;Clinical Cancer Research. 2002 Oct 1
• 34 citations
  A phase I study of SPI-077 (Stealth liposomal cisplatin) concurrent with radiation therapy for locally advanced head and neck cancer.
  David I. Rosenthal, Sue S. Yom, Li Liu, Mitchell Machtay, Kenneth M. Algazy, Randal S. Weber, Gregory S. Weinstein, Ara A. Chalian, Linda Miller, Kenneth Rockwell, Mar...> ;Investigational New Drugs. 2002 Aug 1
• 35 citations
  Phase I Trial of the Cryptophycin Analogue LY355703 Administered as an Intravenous Infusion on a Day 1 and 8 Schedule Every 21 Days
  James P. Stevenson, Weijing Sun, Maryann Gallagher, Robert B. Johnson, David J. Vaughn, Lynn M. Schuchter, Kenneth M. Algazy, Stephen M. Hahn, Nathan Enas, Diane Ellis...> ;Clinical Cancer Research. 2002 Aug 1
• 3 citations
  Spinner's hematuria.
  Algazy, K. M.> ;The New England journal of medicine. 2002 May 25
• 2 citations
  Clinical and Molecular Features of Small cell Lung Cancer
  Allyson M. Campbell, Barbara G. Campling, Kenneth M. Algazy, Wafik S. El-Deiry> ;Cancer Biology & Therapy. 2002 Jan 7
• 35 citations
  Phase I Clinical and Pharmacogenetic Trial of Irinotecan and Raltitrexed Administered Every 21 Days to Patients With Cancer
  James P. Stevenson, Maryann Redlinger, Leo A. J. Kluijtmans, Weijing Sun, Kenneth M. Algazy, Bruce J. Giantonio, Daniel G. Haller, Christine Hardy, Alexander S. Whiteh...> ;Journal of Clinical Oncology. 2001 Oct 15
• 24 citations
  A phase I trial of topotecan and gemcitabine administered weekly for 3 consecutive weeks to patients with advanced tumors.
  Weijing Sun, James P. Stevenson, Maryann Gallagher, Bruce J. Giantonio, Kenneth M. Algazy, Dan Haller, David J. Vaughn, Barbara J. Raskay, Peter J. O'Dwyer> ;Cancer. 2001 Jul 15
• 132 citations
  Factors Affecting the Risk of Brain Metastases After Definitive Chemoradiation for Locally Advanced Non–Small-Cell Lung Carcinoma
  Theodore J. Robnett, Mitchell Machtay, James P. Stevenson, Kenneth M. Algazy, Stephen M. Hahn> ;Journal of Clinical Oncology. 2001 Mar 1
• 13 citations
  Pilot study of organ preservation multimodality therapy for locally advanced resectable oropharyngeal carcinoma
  Mitchell Machtay, David I. Rosenthal, Kenneth M. Algazy, Victor M. Aviles, Ara A. Chalian, Diane Hershock, Robin Neubauer, Michael J. Greenberg, Natasha Mirza, Gregory...> ;American Journal of Clinical Oncology. 2000 Oct 1
• Factors predicting severe radiation pneumonitis in patients receiving definitive chemoradiation for lung cancer.
  Robnett, T. J., Machtay, M., Vines, E. F., McKenna, M. G., Algazy, K. M., McKenna, W. G.> ;Int J Radiat Oncol Biol Phys. 2000 Aug 1
• Join now to see all